Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

About this update from Jaguar Health, Inc.

[{"type":"text","content":"Click here to register","length":22,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which takes place September 8-10, 2025.","length":306,"tagName":"p"},{"type":"text","content":"Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 27th Annual Global Investment Conference","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"When: On-demand virtual presentation available starting at 7:00 AM Eastern on Friday, September 5, 2025","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"Webcast Link: Click here to access the presentation","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"Where: The conference is taking place virtually and in-person at Lotte New York Palace, 455 Madison Avenue at 50th Street, New York City","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"To register to attend the conference, click here","length":48,"tagName":"p","attribs":{}},{"type":"text","content":"About the Jaguar Health Family of Companies","length":43,"tagName":"p"},{"type":"text","content":"Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases...

More updates from Jaguar Health, Inc.